Last Updated : December 23, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Esophageal carcinoma, gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Kineret | anakinra | Still's disease | Withdrawn | |||
Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | ribociclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Received |